Tryptamine Therapeutics (AU:TYP) has released an update.
Tryptamine Therapeutics has enlisted Lucid Health Consulting to bolster the Australian market entry of its IV-infused psilocin treatment, TRP-8803, aiming to fast-track product registration and reimbursement. This strategic move leverages Lucid Health’s expertise in health economics, market access, and regulatory affairs, with the partnership beginning shortly to facilitate ongoing data collection and engagement with the Therapeutic Goods Administration (TGA). TRP-8803 promises to enhance psychedelic therapy by reducing the time to onset, allowing better control of the experience, and shortening the intervention duration.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.
